Hengdi Pharmaceutical (301211.SZ): In the future, it will continue to deepen its traditional advantages in fields such as antipyretic and analgesic, and at the same time pay attention to emerging hotspots such as cough and gout.

Gelonghui Finance · Jun 14 03:19

On June 13, 2024, Hundsun Pharma (301211.SZ) underwent specific object research on "please introduce the company's research and development achievements and impact in the non-steroidal anti-inflammatory drug field", and the company replied that they have long been focused on the research and development of ibuprofen and its series of products. The product line covers multiple links such as active pharmaceutical ingredients, intermediates, and preparations, forming a complete industry chain layout. Through continuous process optimization and quality improvement, the company is among the leading suppliers of ibuprofen in the world. In the future, the company will continue to deepen its traditional advantages in antipyretic and analgesic areas, while paying attention to emerging hotspots in related fields such as cough and gout, enriching pipeline reserves.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more

亨迪药业(301211.SZ)：未来将继续深耕解热镇痛等传统优势领域,同时关注相关领域如止咳、痛风等新兴热点

Hengdi Pharmaceutical (301211.SZ): In the future, it will continue to deepen its traditional advantages in fields such as antipyretic and analgesic, and at the same time pay attention to emerging hotspots such as cough and gout.

Risk Disclaimer

Statement